Everence Capital Management Inc. cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,928 shares of the biopharmaceutical company’s stock after selling 916 shares during the quarter. Everence Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $2,263,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Delphi Private Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $108,000. Atlantic Trust LLC purchased a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at $111,000. Massey Quick Simon & CO. LLC grew its position in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. grew its position in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the last quarter. Finally, Horan Capital Advisors LLC. purchased a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at $122,000. Hedge funds and other institutional investors own 71.55% of the company’s stock.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 4,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is currently owned by insiders.
A number of analysts recently weighed in on BMY shares. TheStreet cut shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. ValuEngine cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Bank of America increased their price target on shares of Bristol-Myers Squibb from $64.00 to $68.00 and gave the company a “neutral” rating in a report on Monday, March 5th. DZ Bank downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, Jefferies Group set a $72.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, February 26th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $66.30.
Bristol-Myers Squibb Co (NYSE BMY) traded down $0.33 during mid-day trading on Wednesday, reaching $66.35. 3,312,683 shares of the company’s stock traded hands, compared to its average volume of 7,973,780. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05. The company has a market capitalization of $109,420.00, a price-to-earnings ratio of 28.09, a price-to-earnings-growth ratio of 2.07 and a beta of 0.98. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The business had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same quarter in the prior year, the company posted $0.63 earnings per share. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. equities research analysts predict that Bristol-Myers Squibb Co will post 3.2 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 2.41%. Bristol-Myers Squibb’s payout ratio is presently 67.80%.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Holdings Cut by Everence Capital Management Inc.” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/03/14/bristol-myers-squibb-co-bmy-position-trimmed-by-everence-capital-management-inc.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.